31 – 40 of 169
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Time to positivity of blood cultures in bloodstream infections with Streptococcus dysgalactiae and association with outcome
(
- Contribution to journal › Article
-
Mark
Microorganisms that commonly cause infective endocarditis- what about Aerococcus in the Duke-ISCVID criteria?
2023) In Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 77(8). p.1217-1219(
- Contribution to journal › Letter
-
Mark
Consequences of Excluding Enterococcus faecium as a Typical Endocarditis Pathogen in the Duke-ISCVID Criteria : Endocarditis Is Endocarditis even if the Bacterium Is Uncommon
(
- Contribution to journal › Letter
- 2022
-
Mark
One Scoring System Does Not Fit All Healthcare Settings
2022) In Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 74(1). p.166-167(
- Contribution to journal › Letter
-
Mark
Surveillance of COVID-19 vaccine effectiveness : A real-time case-control study in southern Sweden
(
- Contribution to journal › Article
-
Mark
COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants: surveillance results from southern Sweden, December 2021 to March 2022
2022)(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2
(
- Contribution to journal › Article
-
Mark
Streptococcus bovis-bacteremia: subspecies distribution and association with colorectal cancer : a retrospective cohort study
(
- Contribution to journal › Article
-
Mark
Blood culture time to positivity in non-β-hemolytic streptococcal bacteremia as a predictor of infective endocarditis-a retrospective cohort study
(
- Contribution to journal › Article
-
Mark
Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases
(
- Contribution to journal › Article